The consolidated result in the first half of the year should reach EUR 2.47 per share (Q2 previous year: EUR 2.59). At the same time sales should run to about EUR 84 million (Q2 previous year: EUR 89 million).
On the basis of this evaluation, and despite Corona, the Executive Board expects the consolidated result for the financial year 2020 to exceed the forecast published at the beginning of the year. It therefore rescinds the previous guidance and increases the target of EUR 3.50 to EUR 4.00 per share. The Executive Board keeps the revenue forecast at EUR 170 million.
The figures are based on the share capital as of 30 June 2020. Converted to the increased share capital of EUR 21,171,932, the forecast is EUR 1.00 per share.
The complete figures for the first half year 2020 will be published on 13 August 2020.
Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Telefon: +49 (30) 941084-0
Telefax: +49 (30) 941084-112
http://www.ezag.de
Öffentlichkeitsarbeit
Telefon: +49 (30) 941084-138
Fax: +49 (30) 941084-112
E-Mail: karolin.riehle@ezag.de
